{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:28:08Z","timestamp":1793363288661,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40263-025-01203-6","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:54:10Z","timestamp":1752166450000},"page":"725-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Investigational Gene Therapies for Parkinson's Disease"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4631-7551","authenticated-orcid":false,"given":"Nicolas","family":"Phielipp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-3030","authenticated-orcid":false,"given":"Claire","family":"Henchcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"6","key":"1203_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737175.2020.1763794","volume":"20","author":"A Merola","year":"2020","unstructured":"Merola A, Van Laar A, Lonser R, Bankiewicz K. Gene therapy for Parkinson\u2019s disease: contemporary practice and emerging concepts. Expert Rev Neurother. 2020;20(6):577\u201390.","journal-title":"Expert Rev Neurother"},{"key":"1203_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.648532","volume":"12","author":"A Merola","year":"2021","unstructured":"Merola A, Kobayashi N, Romagnolo A, Wright BA, Artusi CA, Imbalzano G, et al. Gene therapy in movement disorders: a systematic review of ongoing and completed clinical trials. Front Neurol. 2021;12: 648532.","journal-title":"Front Neurol"},{"issue":"1","key":"1203_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36(1):1\u201312.","journal-title":"Clin Geriatr Med"},{"issue":"9996","key":"1203_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"key":"1203_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","volume":"991","author":"S Fahn","year":"2003","unstructured":"Fahn S. Description of Parkinson\u2019s disease as a clinical syndrome. Ann Ny Acad Sci. 2003;991:1\u201314.","journal-title":"Ann Ny Acad Sci"},{"issue":"10291","key":"1203_CR6","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397(10291):2284\u2013303.","journal-title":"Lancet"},{"issue":"8","key":"1203_CR7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366.","journal-title":"Mov Disord"},{"issue":"s1","key":"1203_CR8","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.3233\/JPD-202100","volume":"10","author":"JL Alberts","year":"2020","unstructured":"Alberts JL, Rosenfeldt AB. The universal prescription for parkinson\u2019s disease: exercise. J Parkinsons Dis. 2020;10(s1):S21\u20137.","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"1203_CR9","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, Smilowska K, Berg D, Corvol JC, et al. European academy of neurology\/movement disorder society-european section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies Mov Disord. 2022;37(7):1360\u201374.","journal-title":"Invasive therapies. Mov Disord."},{"issue":"Pt 10","key":"1203_CR10","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731\u201342.","journal-title":"Brain"},{"issue":"4","key":"1203_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. Randomized delayed-start trial of levodopa in Parkinson\u2019s disease. New Engl J Med. 2019;380(4):315\u201324.","journal-title":"New Engl J Med."},{"issue":"9949","key":"1203_CR12","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"Group PDMC, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196\u2013205.","journal-title":"Lancet"},{"key":"1203_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106040","volume":"122","author":"E Natera-Villalba","year":"2024","unstructured":"Natera-Villalba E, Ruiz-Yanzi MA, Gasca-Salas C, Matarazzo M, Martinez-Fernandez R. MR-guided focused ultrasound in movement disorders and beyond: lessons learned and new frontiers. Parkinsonism Relat Disord. 2024;122: 106040.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"1203_CR14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00702-022-02531-3","volume":"129","author":"SRL Vieira","year":"2022","unstructured":"Vieira SRL, Schapira AHV. Glucocerebrosidase mutations and Parkinson disease. J Neural Transm (Vienna). 2022;129(9):1105\u201317.","journal-title":"J Neural Transm (Vienna)"},{"issue":"s2","key":"1203_CR15","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.3233\/JPD-212724","volume":"11","author":"AD Van Laar","year":"2021","unstructured":"Van Laar AD, Van Laar VS, San Sebastian W, Merola A, Elder JB, Lonser RR, et al. An update on gene therapy approaches for parkinson\u2019s disease: restoration of dopaminergic function. J Parkinsons Dis. 2021;11(s2):S173\u201382.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"1203_CR16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/brain\/awab423","volume":"145","author":"JB Brunet Courssou","year":"2022","unstructured":"Brunet Courssou JB, Durr A, Adams D, Corvol JC, Mariani LL. Antisense therapies in neurological diseases. Brain. 2022;145(3):816\u201331.","journal-title":"Brain"},{"issue":"6","key":"1203_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ymthe.2003.08.021","volume":"8","author":"H Fu","year":"2003","unstructured":"Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X, et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther. 2003;8(6):911\u20137.","journal-title":"Mol Ther"},{"issue":"2","key":"1203_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13861","volume":"140","author":"SF Merkel","year":"2017","unstructured":"Merkel SF, Andrews AM, Lutton EM, Mu D, Hudry E, Hyman BT, et al. Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. J Neurochem. 2017;140(2):216\u201330.","journal-title":"J Neurochem"},{"key":"1203_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.omtm.2023.02.016","volume":"29","author":"H Kawabata","year":"2023","unstructured":"Kawabata H, Konno A, Matsuzaki Y, Hirai H. A blood-brain barrier-penetrating AAV2 mutant created by a brain microvasculature endothelial cell-targeted AAV2 variant. Mol Ther Methods Clin Dev. 2023;29:81\u201392.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"1203_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2019.11.009","volume":"165\u2013166","author":"R Pandit","year":"2020","unstructured":"Pandit R, Chen L, Gotz J. The blood-brain barrier: physiology and strategies for drug delivery. Adv Drug Deliv Rev. 2020;165\u2013166:1\u201314.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9923","key":"1203_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet. 2014;383(9923):1138\u201346.","journal-title":"Lancet"},{"issue":"3","key":"1203_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/humc.2018.081","volume":"29","author":"S Palfi","year":"2018","unstructured":"Palfi S, Gurruchaga JM, Lepetit H, Howard K, Ralph GS, Mason S, et al. Long-term follow-up of a phase i\/ii study of prosavin, a lentiviral vector gene therapy for Parkinson\u2019s disease. Hum Gene Ther Clin Dev. 2018;29(3):148\u201355.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"1203_CR23","unstructured":"Six month follow up data from second cohort SUNRISE PD Phase 2 trial of Axo Lenti PD Gene Therapy. https:\/\/www.globenewswire.com\/news-release\/2020\/10\/06\/2104157\/0\/en\/Axovant-Announces-Positive-Six-Month-Follow-Up-Data-From-Second-Cohort-of-SUNRISE-PD-Phase-2-Trial-of-AXO-Lenti-PD-Gene-Therapy.html. [press release]. 10\/06\/2020 2020. Accessed 18 June 2025."},{"issue":"9","key":"1203_CR24","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"S Muramatsu","year":"2010","unstructured":"Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease. Mol Ther. 2010;18(9):1731\u20135.","journal-title":"Mol Ther"},{"issue":"5","key":"1203_CR25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP, et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann Neurol. 2019;85(5):704\u201314.","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"1203_CR26","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1002\/mds.22062","volume":"23","author":"JA Obeso","year":"2008","unstructured":"Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson\u2019s disease. Mov Disord. 2008;23(Suppl 3):S548\u201359.","journal-title":"Mov Disord"},{"issue":"9579","key":"1203_CR27","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet. 2007;369(9579):2097\u2013105.","journal-title":"Lancet"},{"issue":"4","key":"1203_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10(4):309\u201319.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1203_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"M Niethammer","year":"2017","unstructured":"Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, et al. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease. JCI Insight. 2017;2(7): e90133.","journal-title":"JCI Insight."},{"key":"1203_CR30","doi-asserted-by":"crossref","unstructured":"Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, Dhawan V, et al. Gene therapy reduces Parkinson\u2019s disease symptoms by reorganizing functional brain connectivity. Science translational medicine. 2018;10(469).","DOI":"10.1126\/scitranslmed.aau0713"},{"key":"1203_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/B978-0-323-85555-6.00012-6","volume":"193","author":"RA Barker","year":"2023","unstructured":"Barker RA, Bjorklund A. Restorative cell and gene therapies for Parkinson\u2019s disease. Handb Clin Neurol. 2023;193:211\u201326.","journal-title":"Handb Clin Neurol"},{"key":"1203_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105298","volume":"153","author":"Y Chu","year":"2021","unstructured":"Chu Y, Kordower JH. GDNF signaling in subjects with minimal motor deficits and Parkinson\u2019s disease. Neurobiol Dis. 2021;153: 105298.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1203_CR33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3233\/JPD-212706","volume":"11","author":"A Bjorklund","year":"2021","unstructured":"Bjorklund A. GDNF therapy: can we make it work? J Parkinsons Dis. 2021;11(3):1019\u201322.","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"1203_CR34","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/mds.28258","volume":"35","author":"P Chmielarz","year":"2020","unstructured":"Chmielarz P, Er S, Konovalova J, Bandres L, Hlushchuk I, Albert K, et al. GDNF\/RET Signaling pathway activation eliminates Lewy body pathology in midbrain dopamine neurons. Mov Disord. 2020;35(12):2279\u201389.","journal-title":"Mov Disord"},{"key":"1203_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.714186","volume":"13","author":"S Mitra","year":"2021","unstructured":"Mitra S, Turconi G, Darreh-Shori T, Matlik K, Aquilino M, Eriksdotter M, et al. Increased endogenous GDNF in mice protects against age-related decline in neuronal cholinergic markers. Front Aging Neurosci. 2021;13: 714186.","journal-title":"Front Aging Neurosci."},{"issue":"5","key":"1203_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.14336\/AD.2015.0825","volume":"6","author":"J Budni","year":"2015","unstructured":"Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI. The involvement of BDNF, NGF and GDNF in aging and Alzheimer\u2019s disease. Aging Dis. 2015;6(5):331\u201341.","journal-title":"Aging Dis"},{"issue":"5","key":"1203_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr","year":"2008","unstructured":"Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5):400\u20138.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1203_CR38","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164\u201372.","journal-title":"Lancet Neurol"},{"issue":"18","key":"1203_CR39","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","volume":"80","author":"RT Bartus","year":"2013","unstructured":"Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, et al. Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 2013;80(18):1698\u2013701.","journal-title":"Neurology"},{"key":"1203_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.nbd.2015.03.023","volume":"78","author":"RT Bartus","year":"2015","unstructured":"Bartus RT, Kordower JH, Johnson EM Jr, Brown L, Kruegel BR, Chu Y, et al. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with alpha-synucleinopathies. Neurobiol Dis. 2015;78:162\u201371.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"1203_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"C Warren Olanow","year":"2015","unstructured":"Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol. 2015;78(2):248\u201357.","journal-title":"Ann Neurol"},{"issue":"7","key":"1203_CR42","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/hum.2015.134","volume":"27","author":"WJ Marks Jr","year":"2016","unstructured":"Marks WJ Jr, Baumann TL, Bartus RT. Long-term safety of patients with Parkinson\u2019s disease receiving rAAV2-Neurturin (CERE-120) gene transfer. Hum Gene Ther. 2016;27(7):522\u20137.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"1203_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.23442","volume":"26","author":"RT Bartus","year":"2011","unstructured":"Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson\u2019s disease and nonhuman primate brains. Mov Disord. 2011;26(1):27\u201336.","journal-title":"Mov Disord"},{"issue":"3","key":"1203_CR44","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/brain\/awaa020","volume":"143","author":"Y Chu","year":"2020","unstructured":"Chu Y, Bartus RT, Manfredsson FP, Olanow CW, Kordower JH. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson\u2019s disease. Brain. 2020;143(3):960\u201375.","journal-title":"Brain"},{"issue":"7","key":"1203_CR45","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/mds.27724","volume":"34","author":"JD Heiss","year":"2019","unstructured":"Heiss JD, Lungu C, Hammoud DA, Herscovitch P, Ehrlich DJ, Argersinger DP, et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease. Mov Disord. 2019;34(7):1073\u20138.","journal-title":"Mov Disord"},{"issue":"7","key":"1203_CR46","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ymthe.2023.04.009","volume":"31","author":"MT Rocco","year":"2023","unstructured":"Rocco MT, Akhter AS, Ehrlich DJ, Scott GC, Lungu C, Munjal V, et al. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson\u2019s disease. Mol Ther. 2023;31(7):2296.","journal-title":"Mol Ther"},{"key":"1203_CR47","doi-asserted-by":"crossref","unstructured":"Heiss JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, Scott G, Edwards NA, et al. Persistent GDNF expression 45 months after putaminal infusion of AAV2-GDNF in a patient with Parkinson\u2019s disease. Mov Disord. 2024.","DOI":"10.1002\/mds.29820"},{"key":"1203_CR48","doi-asserted-by":"crossref","unstructured":"Van Laar AD, Christine CW, Phielipp N, Larson PS, Elder JB, Merola A, et al. Intraputaminal delivery of adeno-associated virus serotype 2-glial cell line-derived neurotrophic factor in mild or moderate Parkinson\u2019s disease. Mov Disord. 2025.","DOI":"10.1002\/mds.30193"},{"key":"1203_CR49","doi-asserted-by":"crossref","unstructured":"Uspenskaya O, Mahoney E, Verselis L, Lowrey M, Velaga J, Sevigny J. Design of Phase 1\/2a Study of AAV9-Based gene therapy for Parkinson\u2019s disease with pathogenic GBA1 mutations (PROPEL Trial). Neurology. 2020;94(15).","DOI":"10.1212\/WNL.94.15_supplement.1624"},{"key":"1203_CR50","doi-asserted-by":"crossref","unstructured":"Chung SK, Lee SY. Advances in gene therapy techniques to treat LRRK2 gene mutation. Biomolecules. 2022;12(12).","DOI":"10.3390\/biom12121814"},{"issue":"3","key":"1203_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","volume":"20","author":"DA Kuzmin","year":"2021","unstructured":"Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20(3):173\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"R1","key":"1203_CR52","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1093\/hmg\/ddz148","volume":"28","author":"C Domenger","year":"2019","unstructured":"Domenger C, Grimm D. Next-generation AAV vectors-do not judge a virus (only) by its cover. Hum Mol Genet. 2019;28(R1):R3\u201314.","journal-title":"Hum Mol Genet"},{"issue":"3\u20134","key":"1203_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/hum.2019.274","volume":"31","author":"LF Earley","year":"2020","unstructured":"Earley LF, Conatser LM, Lue VM, Dobbins AL, Li C, Hirsch ML, et al. Adeno-associated virus serotype-specific inverted terminal repeat sequence role in vector transgene expression. Hum Gene Ther. 2020;31(3\u20134):151\u201362.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"1203_CR54","first-page":"147","volume":"32","author":"K McDowell","year":"2024","unstructured":"McDowell K, Ressler R, Wheeler B, Thomas S, Grigoryeva LS, Armendariz A, et al. Systemic AAV gene therapy with CNS targeted engineered capsids achieves significant GCase activity increases in the primate brain to support the potential treatment of GBA-PD. Mol Ther. 2024;32(4):147.","journal-title":"Mol Ther"},{"issue":"3","key":"1203_CR55","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3233\/JPD-202004","volume":"10","author":"RA Barker","year":"2020","unstructured":"Barker RA, Bjorklund A, Gash DM, Whone A, Van Laar A, Kordower JH, et al. GDNF and Parkinson\u2019s disease: where next? A summary from a recent workshop. J Parkinsons Dis. 2020;10(3):875\u201391.","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"1203_CR56","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/mt.2010.106","volume":"18","author":"P Hadaczek","year":"2010","unstructured":"Hadaczek P, Eberling JL, Pivirotto P, Bringas J, Forsayeth J, Bankiewicz KS. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther. 2010;18(8):1458\u201361.","journal-title":"Mol Ther"},{"issue":"11","key":"1203_CR57","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1136\/jnnp-2020-322904","volume":"91","author":"RM Richardson","year":"2020","unstructured":"Richardson RM, Bankiewicz KS, Christine CW, Van Laar AD, Gross RE, Lonser R, et al. Data-driven evolution of neurosurgical gene therapy delivery in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2020;91(11):1210\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1203_CR58","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","volume":"91","author":"RH Bobo","year":"1994","unstructured":"Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91(6):2076\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1203_CR59","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jconrel.2016.02.034","volume":"240","author":"KS Bankiewicz","year":"2016","unstructured":"Bankiewicz KS, Sudhakar V, Samaranch L, San Sebastian W, Bringas J, Forsayeth J. AAV viral vector delivery to the brain by shape-conforming MR-guided infusions. J Control Release. 2016;240:434\u201342.","journal-title":"J Control Release"},{"issue":"4","key":"1203_CR60","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3171\/2015.4.JNS15173","volume":"124","author":"JL Ostrem","year":"2016","unstructured":"Ostrem JL, Ziman N, Galifianakis NB, Starr PA, Luciano MS, Katz M, et al. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson\u2019s disease. J Neurosurg. 2016;124(4):908\u201316.","journal-title":"J Neurosurg"},{"issue":"4","key":"1203_CR61","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3171\/2014.6.PEDS13605","volume":"14","author":"PA Starr","year":"2014","unstructured":"Starr PA, Markun LC, Larson PS, Volz MM, Martin AJ, Ostrem JL. Interventional MRI-guided deep brain stimulation in pediatric dystonia: first experience with the ClearPoint system. J Neurosurg Pediatr. 2014;14(4):400\u20138.","journal-title":"J Neurosurg Pediatr"},{"issue":"6","key":"1203_CR62","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/14737175.2016.1175939","volume":"16","author":"SJ Han","year":"2016","unstructured":"Han SJ, Bankiewicz K, Butowski NA, Larson PS, Aghi MK. Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. Expert Rev Neurother. 2016;16(6):635\u20139.","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"1203_CR63","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s00415-016-8125-0","volume":"263","author":"C Sidiropoulos","year":"2016","unstructured":"Sidiropoulos C, Rammo R, Merker B, Mahajan A, LeWitt P, Kaminski P, et al. Intraoperative MRI for deep brain stimulation lead placement in Parkinson\u2019s disease: 1 year motor and neuropsychological outcomes. J Neurol. 2016;263(6):1226\u201331.","journal-title":"J Neurol"},{"issue":"1","key":"1203_CR64","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","volume":"98","author":"CW Christine","year":"2022","unstructured":"Christine CW, Richardson RM, Van Laar AD, Thompson ME, Fine EM, Khwaja OS, et al. Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 Trial. Neurology. 2022;98(1):e40\u201350.","journal-title":"Neurology"},{"issue":"Pt 8","key":"1203_CR65","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136(Pt 8):2419\u201331.","journal-title":"Brain"},{"key":"1203_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106134","volume":"122","author":"A Van Laar","year":"2024","unstructured":"Van Laar A, Christine C, Phielipp N, Merola A, Elder JB, Larson P, et al. AAV2-GDNF Gene delivery in mild- and moderate-stages of Parkinson\u2019s disease: preliminary brain imaging and clinical outcomes. Parkinsonism Relat Disord. 2024;122: 106134.","journal-title":"Parkinsonism Relat Disord"},{"key":"1203_CR67","unstructured":"Phielipp Nea. Preliminary efficacy of bilateral intraputaminal delivery of GDNF gene therapy (AAV2-GDNF; AB-1005) in Parkinson\u2019s disease: 18-month follow-up from a Phase 1b study [abstract]. Movement Disorders. 2024;39."},{"issue":"5","key":"1203_CR68","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407\u201317.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1203_CR69","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, et al. Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s Progression Markers Initiative Cohort. Mov Disord. 2018;33(5):771\u201382.","journal-title":"Mov Disord"},{"issue":"6","key":"1203_CR70","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"JH Kang","year":"2016","unstructured":"Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression Markers Initiative study. Acta Neuropathol. 2016;131(6):935\u201349.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1203_CR71","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006;60(6):706\u201315.","journal-title":"Ann Neurol"},{"issue":"5","key":"1203_CR72","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/mds.21894","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, et al. Placebo response in Parkinson\u2019s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23(5):690\u20139.","journal-title":"Mov Disord"},{"issue":"2","key":"1203_CR73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/cpt.1970","volume":"109","author":"KT Hall","year":"2021","unstructured":"Hall KT, Vase L, Tobias DK, Dashti HT, Vollert J, Kaptchuk TJ, et al. Historical controls in randomized clinical trials: opportunities and challenges. Clin Pharmacol Ther. 2021;109(2):343\u201351.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1203_CR74","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.1626","volume":"106","author":"KT Hall","year":"2019","unstructured":"Hall KT, Loscalzo J. Drug-placebo additivity in randomized clinical trials. Clin Pharmacol Ther. 2019;106(6):1191\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1203_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.810860","volume":"14","author":"Z Mari","year":"2022","unstructured":"Mari Z, Mestre TA. The disease modification conundrum in Parkinson\u2019s disease: failures and hopes. Front Aging Neurosci. 2022;14: 810860.","journal-title":"Front Aging Neurosci."},{"issue":"10","key":"1203_CR76","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","volume":"21","author":"TM Dawson","year":"2018","unstructured":"Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018;21(10):1370\u20139.","journal-title":"Nat Neurosci"},{"issue":"1","key":"1203_CR77","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4103\/NRR.NRR-D-24-00896","volume":"21","author":"J Chocarro","year":"2026","unstructured":"Chocarro J, Lanciego JL. Adeno-associated viral vectors for modeling Parkinson\u2019s disease in non-human primates. Neural Regen Res. 2026;21(1):224\u201332.","journal-title":"Neural Regen Res"},{"key":"1203_CR78","unstructured":"Whone A. REGENERATE-PD: A Phase 2, randomized, double-blind, surgery-controlled study of GDNF gene therapy (AAV2-GDNF; AB-1005) for moderate stage Parkinson\u2019s disease [abstract]. Movement Disorders. 2024;39."},{"issue":"10","key":"1203_CR79","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/mds.29190","volume":"37","author":"Y Meng","year":"2022","unstructured":"Meng Y, Pople CB, Huang Y, Jones RM, Ottoy J, Goubran M, et al. Putaminal recombinant glucocerebrosidase delivery with magnetic resonance-guided focused ultrasound in Parkinson\u2019s disease: a Phase I study. Mov Disord. 2022;37(10):2134\u20139.","journal-title":"Mov Disord"},{"issue":"5","key":"1203_CR80","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinsons Dis. 2024;14(5):899\u2013912.","journal-title":"J Parkinsons Dis"},{"key":"1203_CR81","unstructured":"MeiraGTx announces positive data from randomized, sham-controlled clinical bridging study of AAV-GAD for the treatment of Parkinson\u2019s disease. https:\/\/investors.meiragtx.com\/news-releases\/news-release-details\/meiragtx-announces-positive-data-randomized-sham-controlled [press release]. 2024. Accessed 18 June 2025."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01203-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01203-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01203-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:52:16Z","timestamp":1757231536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01203-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01203-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nicolas Phielipp MD has received research grants from AskBio. Claire Henchcliffe MD DPhil reports the following conflicts of interest: payments as a consultant for: Abbvie; Guidepoint Global; for participation in scientific advisory boards for: AskBio; Bayer AG; Canary Global, Inc.; Certara; Johnson and Johnson; ProJenX; payment for a lecture from Vertex; payment for serving as a DSMB member for MeiraGTx; and stock options for membership of the Scientific Advisory Board of Axent Biosciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest:"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material:"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Nicolas Phielipp was responsible for conception and study design; collecting data; and writing and revising the manuscript. Claire Henchcliffe was responsible for conception and study design; collecting data; and writing and revising the manuscript. Nicolas Phielipp and Claire Henchcliffe confirm that they have both read and approved the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}